Stock A216080 JETEMA, CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials JETEMA, Co., Ltd.

Equities

A216080

KR7216080002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
15,600 KRW -1.89% Intraday chart for JETEMA, Co., Ltd. -0.06% +0.32%
2023 JETEMA, Co., Ltd. announced that it has received KRW 56 billion in funding from Korea Investment Partners Co. Ltd. CI
2023 JETEMA, Co., Ltd. announced that it expects to receive KRW 56 billion in funding from Korea Investment Partners Co. Ltd. and other investor CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,67,656 4,02,270 3,63,314 2,33,354 2,77,704 2,78,597 - -
Enterprise Value (EV) 1 1,67,661 4,02,270 3,63,287 2,33,440 2,77,704 2,78,597 2,78,597 2,78,597
P/E ratio -9.08 x -42.3 x 33.7 x 144 x 41.6 x 150 x 17.9 x 9.7 x
Yield - - - - - - - -
Capitalization / Revenue 12.6 x - 10.9 x 5.07 x 4.73 x 3.74 x 2.72 x 2.06 x
EV / Revenue 12.6 x - 10.9 x 5.07 x 4.73 x 3.74 x 2.72 x 2.06 x
EV / EBITDA -18.4 x - 135 x 25.6 x 20.4 x 13.3 x 7.74 x 5.36 x
EV / FCF -8 x - -36.6 x -4.9 x - -279 x 27.9 x 12.7 x
FCF Yield -12.5% - -2.73% -20.4% - -0.36% 3.59% 7.9%
Price to Book 3.94 x - 6.66 x 4.1 x - 3.68 x 3.06 x 2.32 x
Nbr of stocks (in thousands) 16,238 17,566 17,766 17,813 17,859 17,859 - -
Reference price 2 10,325 22,900 20,450 13,100 15,550 15,600 15,600 15,600
Announcement Date 30/03/20 19/03/21 24/01/22 09/02/23 15/03/24 - - -
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 13.3 - 33.22 45.99 58.75 74.5 102.4 135
EBITDA 1 -9.123 - 2.694 9.12 13.6 21 36 52
EBIT 1 -10.73 - 2.279 4.378 5.264 12.6 27.2 42
Operating Margin -80.71% - 6.86% 9.52% 8.96% 16.91% 26.56% 31.11%
Earnings before Tax (EBT) 1 -14.72 - 10.88 2.051 3.43 1.9 17.3 34
Net income 1 -14.72 -9.327 11.04 1.622 15.97 1.9 15.6 29
Net margin -110.71% - 33.24% 3.53% 27.19% 2.55% 15.23% 21.48%
EPS 2 -1,136 -541.0 606.0 91.00 374.0 104.0 871.0 1,608
Free Cash Flow 3 -20,960 - -9,921 -47,596 - -1,000 10,000 22,000
FCF margin -1,57,592.07% - -29,861.77% -1,03,482.66% - -1,342.28% 9,765.62% 16,296.3%
FCF Conversion (EBITDA) - - - - - - 27,777.78% 42,307.69%
FCF Conversion (Net income) - - - - - - 64,102.56% 75,862.07%
Dividend per Share - - - - - - - -
Announcement Date 30/03/20 19/03/21 24/01/22 09/02/23 15/03/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 7.3 10.18 9.614 10.31 11.99 14.08 14.15 15.23 16.9 18.5 19.4 19.7
EBITDA - - - - - - - - - - - -
EBIT 1 -1.218 1.717 0.5021 1.06 1.072 1.745 0.5152 2.723 2.7 2.5 4 3.3
Operating Margin -16.69% 16.87% 5.22% 10.27% 8.94% 12.39% 3.64% 17.88% 15.98% 13.51% 20.62% 16.75%
Earnings before Tax (EBT) 1 -2.593 11.75 3.584 8.429 0.5687 -10.53 -3.587 14.72 0.3 -0.1 1.2 0.4
Net income 1 -2.593 11.75 3.584 8.31 0.2591 -10.53 -3.587 27.27 0.3 -0.1 1.2 0.4
Net margin -35.52% 115.4% 37.28% 80.58% 2.16% -74.79% -25.35% 179.07% 1.78% -0.54% 6.19% 2.03%
EPS - - - 98.00 - - - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 15/11/21 24/01/22 13/05/22 12/08/22 14/11/22 09/02/23 14/11/23 15/03/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 4.53 - - 85.9 - - - -
Net Cash position - - 26.7 - - - - -
Leverage (Debt/EBITDA) -0.4965 x - - 9.424 x - - - -
Free Cash Flow 1 -20,960 - -9,921 -47,596 - -1,000 10,000 22,000
ROE (net income / shareholders' equity) - - 22.9% 2.9% - 2.5% 18.6% 27.2%
ROA (Net income/ Total Assets) - - 10.1% 0.87% - 0.8% 6% 9.8%
Assets 2 - - 109 187.4 - 237.5 260 295.9
Book Value Per Share 3 2,619 - 3,071 3,197 - 4,235 5,106 6,714
Cash Flow per Share 3 - - - - - 589.0 1,390 2,178
Capex 2 12.9 - 16.1 61.8 - 11 13 15
Capex / Sales 96.64% - 48.4% 134.3% - 14.77% 12.7% 11.11%
Announcement Date 30/03/20 19/03/21 24/01/22 09/02/23 15/03/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for JETEMA, Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
JETEMA, CO., LTD. Stock JETEMA, Co., Ltd.
+0.32% 203M
CSL LIMITED Stock CSL Limited
-2.61% 89.08B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.55% 40.9B
BIOGEN INC. Stock Biogen Inc.
-14.40% 32.25B
UCB Stock UCB
+55.89% 25.14B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-15.96% 15.39B
INCYTE CORPORATION Stock Incyte Corporation
-15.50% 11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.29% 11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.75% 11.64B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.87% 9.03B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A216080 Stock
  4. Financials JETEMA, Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW